Ulipristal acetate does not impact human normal breast tissue | Zendy

Laudine Communal | Zendy; Myriam Vilasco | Zendy; Justine HugonRodin | Zendy; Aurélie Courtin | Zendy; Najat Mourra | Zendy; N. Lahlou | Zendy; Sylvie Dumont | Zendy; Marc Chaouat | Zendy; Patricia Forgez | Zendy; Anne Gompel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ulipristal acetate does not impact human normal breast tissue

Author(s) -

Laudine Communal,

Myriam Vilasco,

Justine HugonRodin,

Aurélie Courtin,

Najat Mourra,

N. Lahlou,

Sylvie Dumont,

Marc Chaouat,

Patricia Forgez,

Anne Gompel

Publication year - 2012

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/des221

Subject(s) - breast cancer , progesterone receptor , endocrinology , glucocorticoid receptor , medicine , transactivation , cell growth , receptor , cancer research , cancer , biology , estrogen receptor , gene expression , gene , biochemistry , genetics

Antiprogestins are of growing interest for the development of new treatments in the gynecological field. Ulipristal acetate (UPA) is a progesterone receptor (PR) modulator considered for long-term administration in contraception and is currently being registered for the treatment of uterine fibroids. In light of the influences of hormonal dysfunction in breast pathologies, the secondary consequences of chronic UPA therapy need to be established. The aim of this study was to determine UPA actions mediated by PR and glucocorticoid receptor (GR) in normal and transformed breast.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research